Retatrutide Sleep Apnea Trial: USMLE High-Yield Review

Retatrutide, an experimental once-weekly injection that activates three hormone receptors, reduced obstructive sleep apnea (OSA) more than placebo in two phase 3 trials published in the New England Journal of Medicine. The trials enrolled adults with overweight or obesity and moderate-to-severe OSA, with or without type 2 diabetes. For USMLE candidates, the study is a good reason to review OSA pathophysiology, the complications of nocturnal hypoxemia, and the pharmacology of incretin-based drugs.

What happened

Researchers ran two double-blind, randomized, placebo-controlled phase 3 trials. TRIUMPH-1-OSA enrolled patients without type 2 diabetes, and TRIUMPH-2-OSA enrolled patients with it. Participants needed a BMI of at least 27 and at least 15 breathing pauses per hour of sleep. In each trial they were randomized to four equal groups: retatrutide 4 mg, 9 mg, or 12 mg weekly, or placebo.

Treatment lasted about 1.5 years (80 weeks). Participants stayed overnight in a sleep clinic for full polysomnography at baseline, week 24, and week 80.

Reported results:

• All three doses reduced breathing interruptions more than placebo, including in participants with diabetes.
• At the higher doses, 39%–52% of participants improved to no OSA or mild OSA without excessive daytime sleepiness, versus about 13% on placebo.
• At the two higher doses, breathing disruptions fell by an average of 25 per hour (roughly 40%), versus 10 fewer per hour in the placebo group.
• At 4 mg, breathing pauses fell by an average of 23 per hour, and participants lost an average of 12.5% of body weight.
• Among participants without diabetes on 9 mg or 12 mg, 52%–66% cut breathing interruptions by at least half.
• Up to 52% of those without diabetes and 40% of those with diabetes reached normal breathing or only mild OSA.
• In TRIUMPH-2-OSA, average weight loss was 18%–19% with retatrutide versus about 6% with placebo.

Why it matters

OSA is more than snoring. Repeated pauses in breathing and drops in blood oxygen during sleep fragment sleep and can harm long-term health. Excess body weight is a major contributor.

The standard treatment is CPAP, but many people find the mask uncomfortable and struggle to use it every night. The trial asked a different question: what if we treat a modifiable driver of OSA, body weight, instead of only managing the airway?

Retatrutide is a triple receptor agonist (GLP-1, GIP, and glucagon receptors). Its predecessors in the class are semaglutide (Wegovy), which targets one hormone receptor, and tirzepatide (Zepbound), which targets two. If retatrutide is approved, it could become another option for people with obesity and OSA, including those with type 2 diabetes. It is still an investigational drug.

What to know for the USMLE

• Pathophysiology of OSA: Repeated collapse of the upper airway during sleep, when pharyngeal muscle tone falls, causes apneas and hypopneas despite ongoing respiratory effort. Obesity is the classic risk factor, with fat deposition around the neck and pharynx. Other risk factors include male sex, older age, large tonsils, retrognathia, and macroglossia.
• Classic presentation: Loud snoring, witnessed apneas, excessive daytime sleepiness, morning headaches, and impaired concentration. On exam, look for increased neck circumference and obesity.
• Diagnosis: Overnight polysomnography is the gold standard. Severity is graded by the apnea-hypopnea index (AHI), the number of events per hour. Textbook cutoffs are 5–15 mild, 15–30 moderate, and above 30 severe. The trial enrolled people with at least 15 events per hour, which is the moderate-to-severe range.
• Consequences of recurrent hypoxemia and arousals: Sympathetic activation leads to systemic hypertension, including resistant hypertension. Other complications include atrial fibrillation, pulmonary hypertension with cor pulmonale, stroke, insulin resistance, and secondary polycythemia from increased erythropoietin.
• Treatment ladder: Weight loss, CPAP (first-line for moderate-to-severe disease), avoiding alcohol and sedatives before sleep, and positional therapy. Oral mandibular advancement devices, hypoglossal nerve stimulation, and upper airway surgery are alternatives for selected patients.
• Differential: In central sleep apnea there is no respiratory effort during the pause. It is associated with heart failure (Cheyne-Stokes breathing), opioids, and stroke. Obesity hypoventilation syndrome causes daytime hypercapnia, not just nocturnal events.
• Incretin pharmacology: GLP-1 agonists increase glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and promote satiety. GIP also augments insulin secretion, and per the source it contributes to weight reduction alongside GLP-1. Glucagon receptor activation increases energy expenditure.
• Class adverse effects (textbook, not reported in this source for retatrutide): GI symptoms such as nausea and vomiting, plus concerns about pancreatitis and gallbladder disease. GLP-1 agonists carry a boxed warning for medullary thyroid carcinoma and are contraindicated with a personal or family history of it or with MEN2.
• Step 2 CK angle: In a patient with obesity, hypertension, and daytime sleepiness, the next step is a sleep study, not an empiric drug. Weight reduction is part of management, and CPAP remains standard.

Limitations

• Safety data are missing. The source material does not report adverse events, discontinuation rates, or tolerability. Do not infer safety from the efficacy numbers.
• The drug is investigational. The source describes retatrutide as experimental and says "if approved," so it is not an established OSA therapy.
• No head-to-head comparison. The trials compared retatrutide with placebo, not with CPAP or with other weight-loss drugs.
• Summary-level reporting. The source gives some results by dose and some by trial, but not every figure for every group. For example, the 12.5% weight loss is reported for the 4 mg dose without a trial label, and the 18%–19% weight loss is reported for TRIUMPH-2-OSA. Read the full NEJM paper (Grunstein et al.) before quoting exact numbers.
• Remaining questions. The source does not say whether benefits persist after stopping the drug, or how much of the effect comes from weight loss versus other mechanisms.
• The source is a news summary. It is not the primary publication.

FAQ

Does retatrutide treat sleep apnea?

In these two phase 3 trials, it reduced breathing interruptions more than placebo over 80 weeks. It is still experimental, and the source does not report approval.

How is retatrutide different from semaglutide and tirzepatide?

Semaglutide targets one hormone receptor (GLP-1) and tirzepatide targets two (GLP-1 and GIP). Retatrutide also activates the glucagon receptor, which increases energy expenditure.

Could weight-loss drugs replace CPAP?

The source does not say so. It notes that some participants reached normal breathing or mild OSA, levels at which they might no longer need CPAP. The trials did not compare the drug directly with CPAP, so CPAP remains the standard treatment in the source.

Key takeaways

• In two phase 3 trials (TRIUMPH-1-OSA and TRIUMPH-2-OSA), weekly retatrutide reduced OSA severity more than placebo over 80 weeks in adults with overweight or obesity, with or without type 2 diabetes. At higher doses, 39%–52% reached no OSA or mild OSA without excessive daytime sleepiness, versus about 13% on placebo.
• For the USMLE, anchor on OSA basics: obesity as a risk factor, polysomnography and AHI, hypoxemia-driven cardiovascular consequences, and CPAP plus weight loss as treatment. Also know the GLP-1, GIP, and glucagon receptor mechanisms.
• Safety data were not described in the source, and the drug remains investigational, so the findings are promising but incomplete.